Summary of Key Points
Brain-computer interface (BCI) technology is moving from the laboratory to clinical applications. PICC Property and Casualty has launched the first ever insurance product in China specifically for invasive BCI surgeries, filling a gap in risk coverage in this field. However, this is still a customized solution designed for specific hospitals and equipment. There are four major hurdles to overcome before widespread and standardized adoption: establishing unified risk assessment criteria, accumulating sufficient data, developing universal underwriting rules, and establishing a robust reinsurance mechanism. The main challenge is the lack of long-term clinical data on insurance claims. Collaboration among equipment manufacturers, hospitals, and insurance companies is essential to transform this type of insurance from a case-by-case customization to a universally accessible solution.
Detailed Analysis
1. The First Insurance Product: A Customized Solution, Not a Universal One
The insurance provided by PICC Property and Casualty for the Second Affiliated Hospital of Zhejiang University is the first in China to cover invasive BCI surgeries. It addresses unique risks such as cortical bleeding, intracranial infections, and electrode displacement or failure during the procedure, addressing the concern that doctors and patients had no coverage for such surgeries before. Nevertheless, this is a customized product that can only be used for the specific surgical procedures and approved equipment at the Second Affiliated Hospital of Zhejiang University. It would not be applicable at another hospital or with a different BCI device, meaning it is not yet a standard product that can be used nationwide.
2. The Four Major Barriers to Standardized Adoption
To make BCI surgery insurance as widespread as accident insurance for orthopedic or cardiac surgeries, the following four barriers must be overcome:
- Unified Risk Assessment: Different BCI technologies (e.g., whether electrodes are placed inside the cortex or outside the dura mater) carry different risks, and there needs to be a widely recognized risk scoring system.
- Accumulation of Sufficient Data: There are few BCI surgeries to date, and insufficient long-term follow-up data (e.g., 3-10 years of complication rates) are available, making it difficult for insurance companies to determine the appropriate premium.
- Universal Underwriting Rules: It is necessary to clarify who can be insured (e.g., whether they have serious underlying conditions), the qualifications required for hospitals and doctors, and whether the equipment complies with standards.
- Robust Reinsurance: The high risks associated with BCI surgeries mean that a single insurance company cannot afford to handle large claims on its own; therefore, a reinsurance mechanism needs to be established to share the risks.
3. Why is Pricing So Difficult?
The core of insurance pricing is estimating the probability of risk, but there is a significant lack of data for BCI surgeries:
- Lack of Historical Data: BCI technology has only been in clinical use for a short time, and there are few insurance claims to analyze. Insurance companies can only rely on similar, more established procedures (e.g., deep brain stimulation for Parkinson’s disease) for estimation.
- Variation in Equipment: Different brands of BCI equipment have different electrode materials and transmission methods, leading to varying risks and thus different premium rates.
- Patient Differences: The risks associated with surgeries vary depending on the patient's age and immune system; for example, patients with severe cerebrovascular diseases may have higher premiums.
4. Who Will Pay for the Insurance?
The parties responsible for paying for BCI insurance will change as the technology becomes more commercialized:
- Clinical Trial Phase: Companies pay to provide risk coverage for participants and accelerate the adoption of the technology.
- Early Commercialization Phase: Companies and patients share the cost, with companies subsidizing part of the premium to attract patients.
- Regular Application Phase: Patients will pay the full premium, similar to how accident insurance for orthopedic surgeries is currently structured, with the premium included in the treatment cost.
- Future Integration into Medical Insurance: In the future, the cost may be shared by medical insurance, patients, and companies.
5. When Will Widespread Adoption Be Possible?
Widespread adoption of BCI insurance depends on three criteria: universal underwriting rules, coverage of most hospitals and equipment, and stable premium rates supported by a mature reinsurance system. The most critical factor is the availability of sufficient long-term clinical data. Insurance relies on the “law of large numbers”; without enough surgical cases and claims data, it is impossible to establish standard pricing. Therefore, cooperation among equipment manufacturers, hospitals, insurance companies, and regulatory authorities is needed to share data (e.g., de-identified records of surgical complications and equipment failures) while protecting patient privacy, to transition from case-by-case customization to universal coverage.
Conclusion
The launch of this first insurance product represents a significant step forward in risk coverage for the BCI industry. However, to truly benefit a broader range of patients, issues related to data, rules, and collaboration must be addressed. Only by working together to build a solid foundation of risk data can this type of insurance evolve from a niche pilot to a widely available safeguard for the widespread adoption of BCI technology.